161 related articles for article (PubMed ID: 11965836)
1. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.
Sarasombath P; Sumida K; Kaku DA
Hawaii Med J; 2002 Mar; 61(3):48, 57. PubMed ID: 11965836
[TBL] [Abstract][Full Text] [Related]
2. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
[TBL] [Abstract][Full Text] [Related]
3. Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia.
Benelux CML Study Group
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S19-20. PubMed ID: 8769694
[No Abstract] [Full Text] [Related]
4. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
[TBL] [Abstract][Full Text] [Related]
5. Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment.
Chutorian AM; Bojko A; Heier L; Frucht S; Nygaard T; Edelberg D
J Child Neurol; 2003 Nov; 18(11):812-5. PubMed ID: 14696914
[TBL] [Abstract][Full Text] [Related]
6. Hydrocephalic parkinsonism due to Paget's disease of bone: dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy.
Ikeda K; Kinoshita M; Aoki K; Tomatsuri A
Mov Disord; 1997 Mar; 12(2):241-2. PubMed ID: 9087985
[No Abstract] [Full Text] [Related]
7. Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.
Bersano A; Aghemo A; Rumi MG; Ballabio E; Candelise L; Colombo M
Eur J Intern Med; 2008 Jul; 19(5):370-1. PubMed ID: 18549943
[TBL] [Abstract][Full Text] [Related]
8. Juvenile chronic myelogenous leukemia: therapeutic trial with interferon alpha 2B.
Agarwal BR; Gulvady A; Joshi K; Khemani S; Currimbhoy ZE
Indian Pediatr; 1995 Sep; 32(9):1002-4. PubMed ID: 8935266
[No Abstract] [Full Text] [Related]
9. Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients.
Rachmani R; Avigdor A; Youkla M; Raanani P; Zilber M; Ravid M; Ben-Bassat I
Acta Haematol; 1998; 100(4):204-6. PubMed ID: 9973644
[TBL] [Abstract][Full Text] [Related]
10. Development of hyperthyroidism during long term interferon therapy in a patient with chronic myelogenous leukemia: case report.
Ozet A; Ozet G; Calişkaner Z; Kömürcü S; Oztürk B
Endocr J; 1997 Oct; 44(5):715-7. PubMed ID: 9466328
[TBL] [Abstract][Full Text] [Related]
11. [Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
Motomura S; Sakai R; Tomita N; Fujimaki K; Hattori M; Fujisawa S; Mohri H; Takahashi N; Maruta A; Kodama F; Okubo T
Rinsho Ketsueki; 1998 Apr; 39(4):302-7. PubMed ID: 9597898
[TBL] [Abstract][Full Text] [Related]
12. Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report.
Baykal C; Zengin N; Coşkun F; Güler N; Ayhan A
Eur J Gynaecol Oncol; 2000; 21(1):89-90. PubMed ID: 10726630
[No Abstract] [Full Text] [Related]
13. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Nau JY
Rev Med Suisse; 2017 Feb; 13(549):386-387. PubMed ID: 28708364
[No Abstract] [Full Text] [Related]
15. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia.
Arimura K; Arima N; Ohtsubo H; Matsushita K; Kukita T; Ayukawa T; Kuroki T; Tei C
Acta Haematol; 2004; 112(4):217-8. PubMed ID: 15564735
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myelogenous leukemia].
Urabe A
Nihon Rinsho; 2006 Jul; 64(7):1286-90. PubMed ID: 16838646
[TBL] [Abstract][Full Text] [Related]
17. [Interferon-alpha-associated polyarthritis. Possible induction of seropositive rheumatoid arthritis by interferon-alpha: two case reports and review of the literature].
Kötter I; Müller CA; Einsele H; Mohren M; Kanz L
Z Rheumatol; 1999 Aug; 58(4):185-95. PubMed ID: 10502017
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha-induced pure red cell aplasia following chronic myelogenous leukemia.
Tomita N; Motomura S; Ishigatsubo Y
Anticancer Drugs; 2001 Jan; 12(1):7-8. PubMed ID: 11272289
[TBL] [Abstract][Full Text] [Related]
19. Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside.
Patel M; Ezzat W; Pauw KL; Lowsky R
Eur J Haematol; 2001; 67(5-6):318-21. PubMed ID: 11872080
[TBL] [Abstract][Full Text] [Related]
20. Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders.
Beretta L; Caronni M; Vanoli M; Scorza R
Br J Dermatol; 2002 Aug; 147(2):385-6. PubMed ID: 12174121
[No Abstract] [Full Text] [Related]
[Next] [New Search]
